• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of the splenic plasma cells niche that regulate inhibitor production in mice with hemophilia A

Research Project

Project/Area Number 21K07825
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52050:Embryonic medicine and pediatrics-related
Research InstitutionNara Medical University

Principal Investigator

Oda Akihisa  奈良県立医科大学, 医学部, 特任助教 (80547703)

Co-Investigator(Kenkyū-buntansha) 野上 恵嗣  奈良県立医科大学, 医学部, 教授 (50326328)
北畠 正大  奈良県立医科大学, 医学部, 講師 (60457588)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords脾臓 / 微小環境 / 血友病A / 抗FVIII中和抗体 / インヒビター / 間葉系幹細胞 / ニッチ / 補充療法 / 高力価インヒビター / 脾臓微小環境 / ヒト化血友病マウス / 抗FVIII免疫応答 / プラズマ細胞
Outline of Research at the Start

血友病A(HA)に対する第8因子(FVIII)補充療法はHA患者の出血を予防する主要な治療手段である。一方で補充療法を施した約30%の重症HA患者で、治療効果を障害する抗FVIII中和抗体産生(インヒビター)が誘導される。近年、バイパス薬剤やバイスペシフィック抗体等、新規治療法の開発は著しく進展しているが、それらの凝固活性はFVIII補充療法に及ばない。そのためインヒビター産生機序は現在においても解明すべき主要テーマである。本申請研究はレポrーターマウスを用いて、インヒビター産生応答を制御する脾臓免疫ニッチを同定し、インヒビター免疫応答プロセスに関与する標的分子を見出す事を目的としている。

Outline of Final Research Achievements

Hemophilia A (HA) is a hereditary bleeding disorder caused by defects in endogenous factor (F)VIII. Approximately 30% of patients with severe HA treated with FVIII develop neutralizing antibodies (inhibitors) against FVIII, which render the therapy ineffective.
We observed that the enhanced inhibitor production correlates with increased FVIII specific plasma cells especially in the spleen. When splenectomized or congenitally asplenic FVIII-KO mice were treated with LPS+rFVIII, the serum inhibitor levels decreased by approximately 80%. Furthermore, the transplanted plasma cells were preferentially recruited to the spleen, where they were retained and inhibitors were produced. Interestingly, plasma cells ineracted with some splenic cell subset in red pulp of spleen. Taken together, these results suggest that spleen is a critical site for the development and enhancement of FVIII-PCs.

Academic Significance and Societal Importance of the Research Achievements

血友病研究はAAVベクターを用いたFVIII長期発現を可能にする遺伝子治療、またはバイスペシフィック抗体(BsAb)薬の研究が主流となり、補充療法インヒビター産生機序の研究は下火傾向にある。理由は両研究においてインヒビター克服の可能性が示されたからであるが、遺伝子治療被験者数はまだ少数であり、BsAb抗体薬は十分な止血能を有していない事から、破綻性出血時には補充療法を必要とする場合がある。即ちインヒビター問題は未解決である。本研究は一貫してインヒビター産生応答の解明に取り組む。そして抗FVIII免疫応答プロセスを制御する脾臓免疫ニッチという視点から、新規細胞療法候補を当該研究分野へ提供する。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (13 results)

All 2024 2023 2022 2021

All Journal Article (4 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 4 results,  Open Access: 3 results) Presentation (9 results)

  • [Journal Article] The critical role of the histone modification enzyme SETDB2 in the pathogenesis of acute respiratory distress syndrome2023

    • Author(s)
      Sonobe Shota、Kitabatake Masahiro、Hara Atsushi、Konda Makiko、Ouji-Sageshima Noriko、Terada-Ikeda Chiyoko、Furukawa Ryutaro、Imakita Natsuko、Oda Akihisa、Takeda Maiko、Takamura Shiki、Inoue Satoki、Kunkel Steven L.、Kawaguchi Masahiko、Ito Toshihiro
    • Journal Title

      Shock

      Volume: 60 Issue: 1 Pages: 137-145

    • DOI

      10.1097/shk.0000000000002145

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Angiopoietin-like 4 is a critical regulator of fibroblasts during pulmonary fibrosis development2023

    • Author(s)
      Shoichiro Saito, Masahiro Kitabatake, Noriko Ouji-Sageshima, Tatsuro Ogawa, Akihisa Oda, Tomoko Nishimura, Tatsuki Nishioka, Satoki Fushimi, Atsushi Hara, Shigeyuki Shichino, Makiko Kumamoto, Shigeto Hontsu, Takeshi Kawaguchi, Satoshi Ueha, Noriyoshi Sawabata, Shigeo Muro, Kouji Matsushima, Toshihiro Ito
    • Journal Title

      American Journal of Respiratory Cell and Molecular Biology

      Volume: - Issue: 3 Pages: 328-339

    • DOI

      10.1165/rcmb.2022-0304oc

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The spleen is the major site for the development and expansion of inhibitor producing-cells in hemophilia A mice upon FVIII infusion developing high-titer inhibitor2023

    • Author(s)
      Akihisa Oda, Shoko Furukawa, Masahiro Kitabatake, Noriko Ouji-Sageshima, Shota Sonobe, Kaoru Horiuchi, Yuto Nakajima, Kenichi Ogiwara, Ryo Goitsuka, Midori Shima, Toshihiro Ito, Keiji Nogami
    • Journal Title

      Thrombosis research

      Volume: 3848 Pages: 00077-4

    • DOI

      10.1016/j.thromres.2023.03.003

    • Related Report
      2023 Annual Research Report 2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential.2023

    • Author(s)
      Nakajima Y, Takeyama M, Oda A, Shimonishi N, Nogami K.
    • Journal Title

      Blood Advances

      Volume: 7 Issue: 8 Pages: 14361445-14361445

    • DOI

      10.1182/bloodadvances.2022008187

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Establishment of the mouse model with mild/moderate hemophilia A inducible the neutralizing anti-FVIII alloantibodies2024

    • Author(s)
      小田朗永, 古川晶子, 垣本月海, 西村惠子, 野上恵嗣
    • Organizer
      第52回日本免疫学会学術集会,
    • Related Report
      2023 Annual Research Report
  • [Presentation] Angiopoietin-like 4 is a critical mediator for fibroblast activation in pulmonary fibrosis.2024

    • Author(s)
      北畠正大, 王寺典子, 原篤志, 古川龍太郎, 小田朗永, 七野成之, 上羽悟史, 松島綱治, 伊藤利洋
    • Organizer
      第52回日本免疫学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Induction of anti-factor VIII immune response in hemophilia A mouse model retaining humanized immune system.2023

    • Author(s)
      小田朗永, 古川晶子, 北畠正大, 王寺典子, 高橋利一, 荻原建一, 伊藤利洋, 嶋緑倫, 野上恵嗣
    • Organizer
      第85回日本血液学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] in vitro培養系による抗FVIII応答の誘導2023

    • Author(s)
      小田朗永, 古川晶子, 北畠正大, 王寺典子, 堀内薫, 笹井香那, 下西成人, 中島由翔, 荻原建一, 武山雅博, 伊藤利洋, 嶋緑倫, 野上恵嗣
    • Organizer
      第45回日本血栓止血学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 蛍光共鳴エネルギー移動を用いたEmicizumabと活性型第IX因子及び第X因子との三元複合体の評価2023

    • Author(s)
      武山雅博, 小田朗永, 北沢剛久, 野上恵嗣
    • Organizer
      第45回日本血栓止血学会学術集会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Generation of the novel humanized mice with hemophilia A2022

    • Author(s)
      Akihisa Oda, Masahiro Kitabatake, Noriko Ouji-sageshima, Toshikazu Takahashi, Toshihiro Ito, Keiji Nogami
    • Organizer
      第51回日本免疫学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] ヒト化免疫血友病マウスの作製2022

    • Author(s)
      小田朗永、 古川晶子、 北畠正大、 王寺典子、 高橋利一、 能村卓慈、 武山雅博、 伊藤利洋、 嶋緑倫、 野上恵嗣
    • Organizer
      第44回血栓止血学会学術集会
    • Related Report
      2022 Research-status Report
  • [Presentation] Anti-FVIII antibody secreting plasma cells persist in the spleen for extended periods of time in mice with hemophilia A after recombinant FVIII treatment.2021

    • Author(s)
      Akihisa Oda, Masahiro Kitabatake, Toshihiro Ito, Keiji Nogami
    • Organizer
      The 50th Annual Meeting of The Japanese Society for Immunology
    • Related Report
      2021 Research-status Report
  • [Presentation] 血友病Aインヒビター産生細胞の脾臓における動態2021

    • Author(s)
      小田朗永, 中島由翔, 下西成人, 北畠正大, 伊藤利洋, 野上恵嗣
    • Organizer
      第43回日本血栓止血学会学術集会
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi